Related Experiment Video
Updated: Jul 4, 2025
Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions
Published on: April 21, 2016
Apolipoprotein C-III Inhibition - Killing Two Birds with One Stone?
Jordan M Kraaijenhof1, Erik S G Stroes1
1Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam.
Abstract:
In this issue of NEJM Evidence, Gaudet et al.1 report on safety and efficacy of a strategy targeting apolipoprotein C-III (APOC3) using a silencing ribonucleic acid (RNA; ARO-APOC3). In a phase I trial comprising 52 healthy volunteers (triglycerides [TG], >80 mg/dl), 40 patients with hypertriglyceridemia (TG, >300 mg/dl), and 20 patients with chylomicronemia (TG, >880 mg/dl), ARO-APOC3 or placebo was administered subcutaneously either once or twice, with doses given on days 1 and 29. The primary goal was to examine the safety of ARO-APOC3. Injection site reactions were the most commonly observed adverse clinical event; no adverse effects led to discontinuation of the study drug.
Insights
ARO-APOC3, a novel RNA therapy, shows promise in reducing apolipoprotein C-III levels. The phase I trial demonstrated a favorable safety profile, with injection site reactions being the most common side effect.
Area of Science:
- Cardiovascular Science
- Genetics and Molecular Biology
- Pharmacology
Background:
- Hypertriglyceridemia is a significant risk factor for cardiovascular disease.
- Apolipoprotein C-III (APOC3) plays a key role in triglyceride metabolism.
- Targeting APOC3 represents a potential therapeutic strategy for managing dyslipidemia.
Discussion:
- The study evaluated the safety and efficacy of ARO-APOC3, a small interfering RNA (siRNA) targeting APOC3.
- Phase I trial participants included healthy volunteers, patients with hypertriglyceridemia, and those with chylomicronemia.
- The primary endpoint focused on assessing the safety of ARO-APOC3 administration.
Key Insights:
- ARO-APOC3 was administered subcutaneously, with doses given on days 1 and 29.
- The most frequently reported adverse clinical event was injection site reactions.
- No adverse events necessitated the discontinuation of the study drug, indicating a good safety profile.
Outlook:
- Further research is warranted to explore the long-term efficacy and safety of ARO-APOC3.
- This therapeutic approach may offer a new treatment option for patients with severe hypertriglyceridemia.
- Investigating APOC3 inhibition could lead to novel strategies for cardiovascular risk reduction.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...